Removing Barriers to a Clinical Pharmacogenetics Service

• Mallal S , PhillipsE, CarosiGet&#x00A0al.; PREDICT-1 Study Team: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6) , 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes AR , SpreenWR, MostellerM et al.: Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Lennard L , van Loon JA, Lilleyman JS, Weinshilboum RM: Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther.41(1) , 18–25 (1987).
   PubMed Web of Science ®Google Scholar
• Lennard L , van Loon JA, Weinshilboum RM: Pharmacogenetics of acute AZA toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther.46(2) , 149–154 (1989).
   PubMed Web of Science ®Google Scholar
• Tan BB , LearJT, GawkrodgerDJ, English JSC: Azathioprine in dermatology: a survey of current practice in the UK. Br. J. Dermatol.136(3) , 351–355 (1997).
   PubMed Web of Science ®Google Scholar
• Holme SA , DuleyJA, SandersonJ et al.: Erythrocyte thiopurine methyl transferase assessment prior to AZA use in the UK. Q. J. Med.95(7) , 439–444 (2002).
   Google Scholar
• Fargher EA , TrickerK, NewmanW et al.: Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J. Clin. Pharm. Ther.32(2) , 187–195 (2007).
   PubMed Web of Science ®Google Scholar
• Marshall E : Preventing toxicity with a gene test.Science302(5645) , 588–590 (2003).
   PubMed Web of Science ®Google Scholar
• Colombel J -F, Ferrari N, Debuysere H, et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn‘s disease and severe myelosuppression during azathioprine therapy. Gastroenterology118(6) , 1025–1030 (2000).
   PubMed Web of Science ®Google Scholar
• Konstantopoulou M , BelgiA, GriffithsKD, SealeJR, MacfarlaneAW: Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase.BMJ330(7487) , 350–351 (2005).
   PubMedGoogle Scholar
• Tucker G : Pharmacogenetics – expectations and reality.BMJ329(7456) , 4–6 (2004).
   PubMedGoogle Scholar
• The Royal Society: Pharmacogenetics: The Hopes and Realities of Personalised Medicines. A Guide for Health Professionals. The Royal Society, London, UK (2005).
   Google Scholar
• Lunshof JE , PirmohamedM, GurwitzD: Personalized medicine: decades away?Pharmacogenomics7(2) , 237–241 (2006).
   PubMed Web of Science ®Google Scholar
• Shah J : Criteria influencing the clinical uptake of pharmacogenomic strategies.BMJ328(7454) , 1482–1486 (2004).
   PubMedGoogle Scholar
• Department of Health and Human Services:  Realizing the Potential of Pharmacogenomics: Opportunities and Challenges. Report of the Secretary‘s Advisory Committee on Genetics, Health and Society (2008).
   Google Scholar
• Hedgecoe AM : Context, ethics and pharmacogenetics.Stud. Hist. Phil. Biol. Biomed. Sci.37(3) , 566–582 (2006).
   PubMedGoogle Scholar
• Webster A , MartinP, LewisG, SmartA: Integrating pharmacogenetics into society: in search of a model.Nat. Rev. Genet.5(9) , 663–669 (2004).
   PubMed Web of Science ®Google Scholar
• Woolf SH , GrolR, HutchinsonA, Eccles M, Grimshaw J: Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ318(7182) , 527–530 (1999).
   PubMed Web of Science ®Google Scholar
• McGlynn EA , AschSM, AdamsJ et al.: The quality of health care delivered to adults in the United States. N. Engl. J. Med.348(26) , 2635–2645 (2003).
   PubMed Web of Science ®Google Scholar
• Anstey AV , WakelinS, Reynolds NJ; British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee: Guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol.151(6) , 1123–1132 (2004).
   PubMed Web of Science ®Google Scholar
• Chakravarty K , McDonaldH, PullarT et al.: BSR & BHPR guideline for disease-modifying anti-rheumatic drug therapy (DMARD) in consultation with the British Association of Dermatologists. Rheumatology47(6) , 924–925 (2008).
   PubMed Web of Science ®Google Scholar
• Carter MJ , LoboAJ, Travis SP; IBD Section, British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut53(5) , V1–V16 (2004).
   PubMedGoogle Scholar
• Anderson JL , HorneBD, StevensSM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation116(22) , 2563–2570 (2007).
   PubMed Web of Science ®Google Scholar
• Bleecker ER , PostmaDS, LawranceRM, MeyersDA, AmbroseHJ, GoldmanM: Effect of ADRB2 polymorphisms on response to long-acting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies.Lancet370(9605) , 2118–2125 (2007).
   PubMed Web of Science ®Google Scholar
• Innocenti F , UndeviaSD, IyerL et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol.22(8) , 1382–1388 (2004).
   PubMed Web of Science ®Google Scholar
• Hoskins JM , GoldbergRM, QuP, IbrahimJG, McLeodHL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.J. Natl Cancer Inst.99(17) , 1290–1295 (2007).
   PubMedGoogle Scholar
• O‘Dwyer PJ , CatalanoRB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.J. Clin. Oncol.24(28) , 4534–4538 (2006).
   PubMed Web of Science ®Google Scholar
• Carbamazepine: genetic testing recommended in some Asian populations. Drug Safety Update 1(9) , 5 (2008).
   Google Scholar
• Chung WH , HungSI, HongHS et al.: Medical genetics: a marker for Stevens–Johnson syndrome. Nature428(6982) , 486 (2004).
   PubMed Web of Science ®Google Scholar
• Lonjou C , ThomasL, BorotN et al.: A marker for Stevens–Johnson syndrome: ethnicity matters. Pharmacogenomics J.6(4) , 265–268 (2006).
   PubMed Web of Science ®Google Scholar
• Man CB , KwanP, BaumL et al.: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia48(5) , 1015–1018 (2007).
   PubMed Web of Science ®Google Scholar
• Allison M : Is personalized medicine finally arriving?Nat. Biotechnol.26(5) , 509–517 (2008).
   PubMed Web of Science ®Google Scholar
• Goetz MP , KamalA, AmesMM: Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.Clin. Pharmacol. Ther.83(1) , 160–166 (2008).
   PubMed Web of Science ®Google Scholar
• Punglia RS , BursteinHJ, WinerEP, Weeks JC: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J. Natl Cancer Inst.100(9) , 642–648 (2008).
   PubMedGoogle Scholar
• Gardiner SJ , BeggEJ: Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?Pharmacogenet. Genomics15(5) , 365–369 (2005).
   PubMed Web of Science ®Google Scholar
• Wordsworth S , PapanicolasI, BuchananJ, FraylingI, TaylorJ, TomlinsonI: Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories.J. Clin. Pathol.61(3) , 373–376 (2008).
   PubMed Web of Science ®Google Scholar
• Hedgecoe A : Education, ethics and knowledge deficits in clinical pharmacogenetics.Pharmacogenomics8(3) , 267–270 (2007).
   PubMed Web of Science ®Google Scholar
• Gurwitz D , LunshofJE, DedoussisG et al.: Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J.5(4) , 221–225 (2005).
   PubMed Web of Science ®Google Scholar
• Newton R , LithgowJ, Li Wan Po A, Bennett C, Farndon P: How Will Pharmacogenetics Impact on Pharmacy Practice? Pharmacists‘ Views and Educational Priorities. National Genetics Education and Development Centre and The Royal Pharmaceutical Society of Great Britain (2007).
   Google Scholar
• Latif DA , McKayAB: Pharmacogenetics and pharmacogenomics. Instruction in colleges and schools of pharmacy in the United States.Am. J. Pharm. Educ.69 , 23 (2005).
   Web of Science ®Google Scholar
• Brazeau DA , BrazeauGA: A required course in human genomics, pharmacogenomics, and bioinformatics.Am. J. Pharm. Educ.70 , 125 (2006).
   PubMed Web of Science ®Google Scholar
• Gage B , EbyC, JohnsonJ et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther.84(3) , 326–331 (2008).
   PubMed Web of Science ®Google Scholar
• Fargher EA , EddyC, NewmanW et al.: Patients‘ and healthcare professionals‘ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics8(11) , 1511–1519 (2007).
   PubMed Web of Science ®Google Scholar
• Flowers CR , VeenstraD: The role of cost–effectiveness analysis in the era of pharmacogenomics.Pharmacoeconomics22(8) , 481–493 (2004).
   PubMed Web of Science ®Google Scholar
• Drummond M , SculpherM, TorranceGW, O‘BrienBJ, StoddartG: Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Payne K : Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key.Pharmacogenomics9(1) , 1–4 (2008).
   PubMed Web of Science ®Google Scholar
• Payne K , NewmanW, FargherEA, Tricker K, Bruce I, Ollier WER: TPMT testing in rheumatology: any better than routine monitoring? Rheumatology46(5) , 727–729 (2007).
   PubMed Web of Science ®Google Scholar
• Veenstra DL , HarrisJ, GibsonRL, RosenfeldM, BurkeW, WattsC: Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.Genet. Med.9(10) , 695–704 (2007).
   PubMed Web of Science ®Google Scholar
• Sculpher MJ , DrummondMF, BuxtonMJ: The iterative use of economic evaluation as part of the process of health technology assessment.J. Health Serv. Res. Policy2 , 26–30 (1997).
   PubMedGoogle Scholar
• Ryan M , GerardK: Using discrete choice experiments to value healthcare programmes: current practice and future research reflections.Appl. Health Econ. Health Pol.2(1) , 55–64 (2003).
   PubMedGoogle Scholar
• Fargher EA , NewmanW, EddyC et al.: Exploring patients‘ and healthcare professionals‘ preferences for pharmacogenetic testing services. Presented at: Pharmacogenomics, Joint Cold Spring Harbor Laboratory/Wellcome Trust Conference. Hinxton, Cambridge, UK, 17–20 October 2007.
   Google Scholar
• Hedgecoe AM : The Politics of Personalised Medicine – Pharmacogenetics in the Clinic. Cambridge University Press, Cambridge, UK (2004).
   Google Scholar
• Hedgecoe AM : From resistance to usefulness: sociology and the clinical use of genetic tests.BioSocieties3(2) , 183–194 (2008).
   Web of Science ®Google Scholar

Websites

• Sandwell and West Birmingham Hospitals Clinical Biochemistry News – City Hospital www.cityassays.org.uk/downloads/ClinChem%20Ext%20News%2005%20April%202007.pdf
   Google Scholar
• British Society for Rheumatology Clinical Guidelines: Other Topics www.rheumatology.org.uk/guidelines/guidelines_other
   Google Scholar
• British HIV Association Guidelines www.bhiva.org/cms1191540.asp
   Google Scholar
• National Genetics Education and Development Center www.geneticseducation.nhs.uk
   Google Scholar
• Pharmacogenetics Education Resource for Physicians www.pharmacogeneticsworkinggroup.org/educationmaterials/index.html
   Google Scholar
• Genetics Education Program for Nurses http://gepn.cchmc.org
   Google Scholar
• Warfarin-dosing website www.warfarindosing.com
   Google Scholar